Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Time to Sell?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped down before the market opened on Tuesday . The stock had previously closed at $33.79, but opened at $30.54. Nanobiotix shares last traded at $30.49, with a volume of 3,760 shares trading hands.

Wall Street Analysts Forecast Growth

Several research firms have commented on NBTX. Guggenheim raised their target price on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. TD Cowen restated a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Nanobiotix Trading Up 4.5%

The firm’s 50 day moving average is $30.77 and its 200 day moving average is $24.95.

Nanobiotix (NASDAQ:NBTX) last posted its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $3.42 million during the quarter. Equities analysts predict that Nanobiotix S.A. – Sponsored ADR will post 0.53 EPS for the current year.

Hedge Funds Weigh In On Nanobiotix

Institutional investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new stake in Nanobiotix during the fourth quarter valued at about $390,000. Marshall Wace LLP acquired a new stake in Nanobiotix during the 4th quarter valued at $220,000. Optiver Holding B.V. purchased a new stake in shares of Nanobiotix in the third quarter valued at $101,000. Finally, Royal Bank of Canada grew its holdings in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.